SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/312111"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/312111" > Longitudinal Data i...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003836naa a2200493 4500
001oai:gup.ub.gu.se/312111
003SwePub
008240528s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:234150357
024a https://gup.ub.gu.se/publication/3121112 URI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:2341503572 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Bountouvi, Evangelia4 aut
2451 0a Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxylpropyl-β-cyclodextrin.
264 1c 2021
520 a Niemann-Pick Type C disease (NPC) is a rare, incurable, autosomal-recessive, lysosomal storage disorder with protean and progressive neurovisceral manifestations characterized by accumulation of intracellular unesterified cholesterol. The investigational use of 2-hydroxypropyl-beta-cyclodextrin (HP-β-CD) in the treatment of NPC has shown promising results in improving life expectancy and reducing neurological damage in this patient population. This case report describes two children with the neurological form of NPC: a 5-year-old male patient in advanced stage of the disease and an 11-year-old female patient in moderately advanced stage. Despite treatment with the enzyme inhibitor, miglustat, both patients continued to exhibit severe neurodegeneration. High intrathecal (900mg) and low intravenous (350-500mg/kg) doses of HP-β-CD (Trappsol®Cyclo™) were administrated twice monthly to the patients in addition to miglustat therapy. The patients were monitored clinically as well as by imaging, laboratory, and biomarker (e.g., total tau protein [T-tau]; phosphorylated tau [P-tau]; neurofilament light [NFL], oxysterols) studies over a period of 16 to 22 months. The combination therapy of miglustat and HP-β-CD resulted in disease stabilization in both patients. The combination therapy demonstrated a good safety profile, and no adverse effects on hearing were observed. Additionally, CSF biomarkers appeared useful in monitoring neuronal damage. Large, randomized studies are needed to confirm these findings.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
653 a Niemann-Pick type C disease (NPC)
653 a adverse events
653 a cyclodextrin
653 a biomarkers
653 a neurofilament light (NFL)
653 a phosphorylated tau (P-tau)
653 a total tau protein (T-tau)
700a Giorgi, Melpomeni4 aut
700a Papadopoulou, Anna4 aut
700a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka
700a Björkhem, Ingemaru Karolinska Institutet4 aut
700a Tsirouda, Maria4 aut
700a Kanellakis, Spyridon4 aut
700a Fryganas, Andreas4 aut
700a Spanou, Maria4 aut
700a Georgaki, Ioanna4 aut
700a Asprogeraka, Sofia4 aut
700a Dinopoulos, Argyrios4 aut
710a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org
773t Innovations in clinical neuroscienceg 18:1-3, s. 11-16q 18:1-3<11-16x 2158-8333
8564 8u https://gup.ub.gu.se/publication/312111
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:234150357

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy